Maze’s MZE782 showed strong Phase 1 results, supporting once- or twice-daily dosing with increased amino acid excretion and no serious side effects.
Maze Shares Jump As Investors Bet Big On Experimental Treatment’s Potential
Where Today's News Shapes Tomorrow
